Patients with chronic spontaneous urticaria experienced early symptom improvements that were sustained through 52 weeks with remibrutinib, according to a presentation at the European Academy of Allergy & Clinical Immunology Congress. The safety profile for the Bruton’s tyrosine kinase (BTK) inhibitor was favorable and consistent through 52 weeks as well, the researchers said.
MELBOURNE, Australia, June 1, 2023 /PRNewswire/ The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax, which is developing the novel therapy PVX108 for the safe and convenient treatment of peanut allergy. The study is being conducted under a U.S. FDA Investigational New Drug Application. Allergy clinical trial centres across Victoria, South Australia, New South Wales, and Western Australia have invited children and adolescents aged four to 17 years with peanut allergy to take part in the Phase 2 study. Researchers aim to evaluate the efficacy of the novel therapy PVX108. In Phase 1 trials, researchers observed that PVX108 produced relevant changes in the immune response to peanut protein, which continued to develop once dosing had completed. "We're thrilled to have dosed our first patient in Phase 2. In this Phase 2 trial we will evaluate how the immunological changes observed in Phase 1 trials translate to clinical reductions
Aravax doses first patient in Phase 2 peanut allergy clinical trials fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.